Hamilton Nicholas B, Arns Steve, Shelley Mee, Bechis Irene, Shelley John C
Schrödinger, Inc., 101 SW Main Street, Suite 1300, Portland Oregon 97204, United States!
Acuitas Therapeutics, 6190 Agronomy Road, Suite 405, Vancouver, British Columbia, Canada V6T 1Z3.
Mol Pharm. 2025 Jan 6;22(1):588-593. doi: 10.1021/acs.molpharmaceut.4c00426. Epub 2024 Dec 10.
Creating new ionizable lipids for use in lipid nanoparticles (LNPs) is an active field of research. One of the critical properties for selecting suitable ionizable lipids is the apparent p value of the lipid as formulated in an LNP. We have developed a structure-based, computational methodology for the prediction of the apparent p value of ionizable lipids within LNPs and have tested it using the lipid formulations in the mRNA LNP COVID-19 vaccines COMIRNATY and Spikevax, and the siRNA LNP therapeutic Onpattro. The calculation was also applied to Lipid A, a variant of the ionizable lipid used in COMIRNATY.
开发用于脂质纳米颗粒(LNP)的新型可电离脂质是一个活跃的研究领域。选择合适的可电离脂质的关键特性之一是其在LNP中配制时的表观p值。我们已经开发了一种基于结构的计算方法,用于预测LNP中可电离脂质的表观p值,并使用mRNA LNP COVID-19疫苗COMIRNATY和Spikevax以及siRNA LNP治疗药物Onpattro中的脂质配方对其进行了测试。该计算方法还应用于脂质A,它是COMIRNATY中使用的可电离脂质的一种变体。